Objective: This study aims to estimate the up-to-date prevalence of overweight/obesity in the suburban area of Beijing, China, and its associations with hypertension, diabetes, dyslipidemia, and metabolic syndrome (MetS). Methods: A cross-sectional survey in 19,003 suburban adults was carried out in Beijing, 2007. Overweight and obesity class 1, 2, and 3 were defined as a body mass index (BMI) of 25.0–29.9, 30.0–34.9, 35.0–39.9, and = 40 kg/m2, respectively. Results: The age-standardized prevalence of overweight/obesity was 31.9% in the study. With increasing BMI, the prevalence of hypertension, diabetes, dyslipidemia, and MetS also increased. With normal body weight as reference, the adjusted odds ratio (95% confidence interval) of hypertension for overweight and obesity class 1–3 was 2.5 (2.2–2.7), 3.1 (2.8–3.4), 3.6 (3.1–4.3), and 4.5 (4.0–5.2), respectively. The same trend was observed for diabetes and MetS. For dyslipidemia, however, participants with obesity class 2 had the highest odds ratio. Conclusion: The prevalence of hypertension, diabetes, dyslipidemia, and MetS increases with increasing BMI. Overweight/obesity is an important risk factor for these diseases. To reduce the social burden of these obesity-related diseases, effective strategies for the prevention of overweight/obesity should be implemented.

Keywords:
Overweight, Obesity, Diabetes, Hypertension, Dyslipidemia, Metabolic syndrome
This content is only available via PDF.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.